Targeting only the tumor stroma with DC-shA20-FAP resulted in the induction of TRP2-specific TILs and systemic TRP2-specific T-cell responses that were higher (although not significant) in comparison to the DC-sh-TRP2 vaccine. This evidence concerns the gene FAP and neoplasm.